Alternative Data for Capricor Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 19 | Sign up | Sign up | Sign up |
| Sentiment | 82 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 6 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,235 | Sign up | Sign up | Sign up |
| Instagram Followers | 6,161 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Subscribers | 366 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,139 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 30,306 | Sign up | Sign up | Sign up |
| X Followers | 2,587 | Sign up | Sign up | Sign up |
| X Mentions | 42 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 58 | Sign up | Sign up | Sign up |
| Linkedin Employees | 222 | Sign up | Sign up | Sign up |
About Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
| Price | $30.50 |
| Target Price | Sign up |
| Volume | 2,669,093 |
| Market Cap | $1.66B |
| Year Range | $4.6 - $33.57 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)March 12 - GlobeNewswire |
|
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLAMarch 10 - GlobeNewswire |
|
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12March 9 - GlobeNewswire |
|
Capricor Therapeutics Announces Its Data From Phase 3 HOPE-3 Clinical Trial Of Deramiocel In Duchenne Muscular Dystrophy Selected For Presentation At 2026 Muscular Dystrophy Association Clinical And Scientific ConferenceFebruary 23 - Benzinga |
|
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline DataJanuary 20 - GlobeNewswire |
|
 |
Capricor Therapeutics: A High Risk/High Reward NameJanuary 9 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 20M | -20M | -25M | -24M | -0.540 |
| Q2 '25 | 0 | 22M | -22M | -26M | -27M | -0.570 |
| Q1 '25 | 0 | 19M | -19M | -24M | -25M | -0.530 |
| Q4 '24 | 11M | 15M | -3.4M | -7.1M | -7.3M | -0.160 |
| Q3 '24 | 2.3M | 12M | -9.5M | -13M | -13M | -0.380 |
Insider Transactions View All
| Nippon Shinyaku Co Ltd filed to buy 7,090,351 shares at $5.4. September 24 '24 |
| Musket David B filed to buy 31,536 shares at $2.8. October 13 '23 |
| COLLIER EARL M JR filed to buy 26,856 shares at $2.8. October 12 '23 |
| Musket David B filed to buy 31,126 shares at $2.8. October 11 '23 |
| Auwaerter Paul Gisbert filed to buy 5,000 shares at $2.8. October 10 '23 |
Similar companies
Read more about Capricor Therapeutics (CAPR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, reddit subscribers, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Capricor Therapeutics
The Market Cap of Capricor Therapeutics is $1.66B.
Currently, the price of one share of Capricor Therapeutics stock is $30.50.
The CAPR stock price chart above provides a comprehensive visual representation of Capricor Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Capricor Therapeutics shares. Our platform offers an up-to-date CAPR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Capricor Therapeutics (CAPR) does not offer dividends to its shareholders. Investors interested in Capricor Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Capricor Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
